Aimmune Therapeutics
Aimmune Therapeutics is a biopharmaceutical company developing oral immunotherapies for food allergies. Its lead product, Palforzia, was the first FDA-approved peanut allergy treatment. Founded in 2011 and now a wholly-owned subsidiary of Nestlé Health Science USA following a 2020 acquisition.
- Company typePrivate
- Founded2011
- HeadquartersBrisbane, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aimmune Therapeutics does
Aimmune Therapeutics is a clinical- and commercial-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California, that develops oral immunotherapy (OIT) treatments for food allergies. Its lead asset, Palforzia (formerly AR101), is a peanut-derived oral biologic regimen that received FDA approval in January 2020 as the first treatment indicated for peanut allergy in children and adolescents ages 4 through 17, and is administered under a Risk Evaluation and Mitigation Strategy (REMS) with structured up-dosing in supervised clinical settings. The company monetizes through prescription drug sales to patients via specialty pharmacies, allergists, and pediatricians, with go-to-market expanded through integration into Nestlé Health Science's Pharmaceutical Therapies commercial and medical-affairs infrastructure across North America, 16 European countries, and Australia. In February 2020, Nestlé Health Science completed a $2.1 billion acquisition of Aimmune, taking the company private; Aimmune now operates as a wholly-owned subsidiary of Nestlé Health Science USA, with 501–1,000 employees supporting continued food-allergy pipeline and Palforzia commercialization. The business model is therefore a specialty biopharma commercial-stage franchise embedded within a global nutrition and pharmaceutical parent's distribution, reimbursement, and regulatory footprint, with revenue not separately disclosed at the subsidiary level.
Aimmune Therapeutics firmographics
Firmographics- Name
- Aimmune Therapeutics
- Legal name
- Aimmune Therapeutics, Inc.
- Website
- https://aimmune.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Aimmune Therapeutics is a biopharmaceutical company developing oral immunotherapies for food allergies. Its lead product, Palforzia, was the first FDA-approved peanut allergy treatment. Founded in 2011 and now a wholly-owned subsidiary of Nestlé Health Science USA following a 2020 acquisition.
- Ownership category
- akta.pro rank
Aimmune Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)
- akta.pro secondary industries
- Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where Aimmune Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- United States
- HQ region
- North America
Markets served
Aimmune Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Aimmune Therapeutics product offering
Product offeringCore offering
Aimmune Therapeutics is a biopharmaceutical company that develops and commercializes oral immunotherapies for food allergies. Its lead product, Palforzia (formerly AR101), is an FDA-approved oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.
Differentiator
Problem solved
Functional benefit
Brands
- Palforzia: The first FDA-approved oral immunotherapy for peanut allergy, formerly known as AR101. Marketed for children and adolescents ages 4 through 17 with a confirmed diagnosis of peanut allergy.
Products and services
- Palforzia (formerly AR101) Palforzia is an oral immunotherapy product designed to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. It is indicated for children and adolescents ages 4 through 17 with a confirmed diagnosis of peanut allergy, and is used under the supervision of an allergist as part of a Risk Evaluation and Mitigation Strategy (REMS) program.
Companies that use Aimmune Therapeutics
Customer profileIdeal customer profiles1 record
Aimmune Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aimmune Therapeutics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Aimmune Therapeutics competitors and assessment
Company assessmentEmerging players
- Aravax: Aravax is a clinical-stage company developing peptide-based immunotherapies for peanut allergy, representing an emerging food allergy immunotherapy competitor comparable to Aimmune's core focus.
- Prota Therapeutics: Prota Therapeutics is developing an oral immunotherapy for peanut allergy (PRT120), directly comparable to Palforzia as a clinical-stage peanut OIT competitor.
- Alladapt Immunotherapeutics: Alladapt is a clinical-stage biotech developing multi-food allergen oral immunotherapy, directly comparable to Aimmune's OIT modality for food allergy desensitization.
Broad incumbents
- Novartis: Novartis is a broad biopharma with respiratory and immunology franchises overlapping Aimmune's allergy therapeutic focus, and has the scale and commercial reach comparable to Nestlé Health Science as a parent competitor.
- ALK-Abelló: ALK-Abelló is the global leader in allergy immunotherapy (SCIT/SLIT) for respiratory and venom allergies, comparable to Aimmune as a commercial-stage allergy immunotherapy company expanding into food allergy.
- Sanofi: Sanofi markets Dupixent (dupilumab), which is approved for various allergic conditions and has been studied in food allergy adjunction settings, positioning it as a broad incumbent competing in the same therapeutic category.
- Regeneron: Regeneron co-developed Dupixent and has active immunology and food allergy research programs, making it a relevant broad incumbent biopharma peer to Aimmune's biologic allergy work.
- Genentech (Roche): Genentech has active immunology research including IgE-mediated disease programs, making it a relevant broad incumbent biopharma operating in the same therapeutic biology as Aimmune.
Direct peers
- DBV Technologies: DBV Technologies is developing Viaskin Peanut, an epicutaneous immunotherapy for peanut allergy, making it the most directly comparable competitor to Aimmune's Palforzia in the same indication and patient population.
- Stallergenes Greer: Stallergenes Greer is a specialty biopharmaceutical company focused on allergy immunotherapy (subcutaneous and sublingual), making it a directly comparable allergy desensitization therapeutics peer to Aimmune.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Aimmune Therapeutics social profiles
Digital presenceAimmune Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aimmune Therapeutics leadership team
Management profileNumber of profiles
Aimmune Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aimmune Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aimmune Therapeutics
What does Aimmune Therapeutics do?
Aimmune Therapeutics is a biopharmaceutical company that develops and commercializes oral immunotherapies for food allergies. Its lead product, Palforzia (formerly AR101), is an FDA-approved oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.
Is Aimmune Therapeutics a public or private company?
Aimmune Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Aimmune Therapeutics founded?
Aimmune Therapeutics was founded in 2011. It employs 501 to 1,000 people.
Where is Aimmune Therapeutics based?
Aimmune Therapeutics is headquartered in Brisbane, United States, in the North America region.
Who are Aimmune Therapeutics's main competitors?
Emerging players on record are Aravax, Prota Therapeutics and Alladapt Immunotherapeutics. Broad incumbents are Novartis, ALK-Abelló, Sanofi, Regeneron and Genentech (Roche). Direct peers are DBV Technologies and Stallergenes Greer.
Does Aimmune Therapeutics have an API?
No public API is recorded for Aimmune Therapeutics.
What industry is Aimmune Therapeutics in?
Aimmune Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization), with a secondary code of HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services. Its NAICS code is 325414 and its SIC code is 2836.